The U.S. Food and Drug Administration (USFDA) has concluded the inspection at Natco Pharma’s pharma division located in Kothur, Hyderabad, India. The said inspection was conducted from June 09 to June 19, 2025.
On conclusion of the inspection, the Company received seven observations in the Form-483. The company remains committed to being cGMP compliant and in supplying high-quality products to its customers and patients globally.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.
